OUR SCIENCE - PBD-PSC TECHNOLOGY
We hold the exclusive license and right to market and sell, in all territories throughout the world, animal applications of an advanced technology, including all products, methods, processes and procedures related to the ability to harvest, in therapeutic quantities, a distinct population of peripheral blood derived parathyroid hormone receptor positive pluripotent stem cells, initially isolated from adipose-tissue, but found in abundance in bone marrow, from where they originate, and as also discovered by Tithon’s researchers, to be present in abundance in peripheral blood.
These cells express a unique marker that can be used to select them for both diagnostic and therapeutic procedures utilizing a proprietary antibody on its own or in combination with existing commercially available antibodies incorporated into a proprietary method and process developed by Tithon, that we have branded as PRIMOSTEM CPStm.
Tithon’s scientists, based on early clinical research, have shown that these characteristics suggest that these cells will play a significant role in future stem cell based therapeutic and regenerative applications in treating animal degenerative medical conditions, requiring the regeneration of various tissues within the ectoderm, endoderm and mesoderm cell layers, along with certain degenerative states.
Furthermore, unlike bone marrow, or adipose tissue derived stem cells, these PBD-PSC stem cells derived from peripheral blood utilizing our PRIMOSTEM CPStm system
Are derived from peripheral blood and require no anesthesia and liposuction and no bone marrow aspiration and associated risks and commonly reported pain and healing time, making clinical therapies using our PRIMOSTEM CPStm system simple and safe.
Are pluripotent in nature capable of producing progenitor cells for every type of tissue in the body, thereby expanding currently available therapeutic applications.
Are available in sufficient quantities in the peripheral blood to produce therapeutic quantities without required cell culturing.
Tithon researchers, in collaboration with Veterinarian medical professionals and university researchers, have begun to observe substantial improvements in a number of degenerative medical conditions experienced by both companion animals and horses.